6,7-dihydro-2-ethyl-5H-1-pyridine | 30564-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6,7-dihydro-2-ethyl-5H-1-pyridine
• 英文别名: 2,3-Cyclopenteno-6-ethylpyridin；2-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridine
• CAS: 30564-54-6
• 化学式: C₁₀H₁₃N
• 分子量: 147.22
• InChiKey: SDLHYTNDMOFBKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,3-环戊烯并吡啶 、 乙烯 在 (C₅Me₅)Sc(CH₂C₆H₄NMe₂-o)2 、 tris(pentafluorophenyl)borane 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以94%的产率得到6,7-dihydro-2-ethyl-5H-1-pyridine
  参考文献：
  名称：

  Rare-Earth-Catalyzed C–H Bond Addition of Pyridines to Olefins

  摘要：

  An efficient and general protocol for the ortho-alkylation of pyridines via C-H addition to olefins has been developed, using cationic half-sandwich rare-earth catalysts, which provides an atom-economical method for the synthesis of alkylated pyridine derivatives. A wide range of pyridine and olefin substrates including alpha-olefins, styrenes, and conjugated dienes are compatible with the catalysts.

  DOI：

  10.1021/ja208129t

文献信息

• COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION
  申请人：Cleave Biosciences, Inc.

  公开号：US20140235548A1

  公开（公告）日：2014-08-21

  Compounds, pharmaceutical compositions, and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by JAMM proteins are disclosed. The compounds and compositions inhibit the enzymatic activity of a JAMM domain, including the JAMM domain of the CSN5 subunit of the COP9-signalsome (CSN), the JAMM domain of the Rpn11/Poh1/Psmd14 subunit of the 26S proteasome, the JAMM domain of AMSH, the JAMM domain of AMSH-LP, the JAMM domain of BRCC36, among other JAMM domains.

  本文介绍了化合物、药物组合物以及使用这些化合物治疗或预防与JAMM蛋白相关或介导的疾病或障碍的方法。这些化合物和组合物抑制JAMM域的酶活性，包括COP9信号体（CSN）的CSN5亚基的JAMM域、26S蛋白酶的Rpn11/Poh1/Psmd14亚基的JAMM域、AMSH的JAMM域、AMSH-LP的JAMM域、BRCC36的JAMM域等其他JAMM域。
• A new pyridine synthesis
  作者：T. Ross Kelly、Hshiouting Liu

  DOI：10.1021/ja00303a031

  日期：1985.8
• KELLY, T. R.;LIU, HSHIOU-TING, J. AMER. CHEM. SOC., 1985, 107, N 17, 4998-4999
  作者：KELLY, T. R.、LIU, HSHIOU-TING

  DOI：——

  日期：——
• [EN] HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU VRS
  申请人：ENANTA PHARM INC

  公开号：WO2019006291A1

  公开（公告）日：2019-01-03

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• [EN] HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE VRS
  申请人：ENANTA PHARM INC

  公开号：WO2019199908A1

  公开（公告）日：2019-10-17

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.